In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Caris Life Sciences trades well above its PERT-weighted fair value of $10.85, indicating significant overvaluation with a -41.4% implied downside. The DCF analysis reveals deeply negative intrinsic value, contrasting sharply with optimistic analyst targets and trading ranges. Poor profitability and growth metrics combined with a high liquidity score suggest financial distress risks despite strong cash positions.